The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
Open accessAbstract
SUMMARY Uveal melanoma (UM) is the most common cancer in adult eyes. Approximately eighty percent of UMs harbor somatic activating mutations in GNAQ or GNA11 (encodes Gq or G11 respectively). Herein, we show in both cell culture and human tumors that cancer-associated Gq/11 mutants activate YAP, a major effector of the Hippo tumor suppressor pathway that is also regulated by G-protein coupled receptor (GPCR) signaling. YAP mediates the oncogenic activity of mutant Gq/11 in UM development, and the YAP inhibitor verteporfin blocks tumor growth of UM cells containing Gq/11 mutations. This study reveals an essential role of the Hippo-YAP pathway in Gq/11-induced tumorigenesis and suggests YAP as a potential drug target for UM patients carrying mutations in GNAQ or GNA11.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Self-citationTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
Self-citationThe Hippo Signaling Pathway in Development and Cancer
Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.09.011 · Cited by 2,269
The Hippo pathway and human cancer
Harvey, K. F., Zhang, X., & Thomas, D. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3458 · Cited by 1,842
Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling
Yu, F.-X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.037 · Cited by 1,628
Self-citationFrequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
Self-citationMutations in GNA11 in Uveal Melanoma
Van Raamsdonk, C. D., Griewank, K. G., Crosby, M. B., Garrido, M. C., Vemula, S., Wiesner, T., Obenauf, A. C., Wackernagel, W., Green, G., Bouvier, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000584 · Cited by 1,476
Self-citationLiu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452
The Hippo pathway: regulators and regulations.
Yu, F.-X., & Guan, K.-L. (2013) · Genes & Development · doi:10.1101/gad.210773.112 · Cited by 1,231
Self-citationSturge–Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation in GNAQ
Shirley, M. D., Tang, H., Gallione, C. J., Baugher, J. D., Frelin, L. P., Cohen, B., North, P. E., Marchuk, D. A., Comi, A. M., & Pevsner, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213507 · Cited by 1,096
Cited by
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
Self-citationYAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667
“Concordantly, YAP and TAZ have been considered as therapeutic targets for a number of cancers (Liu-Chittenden et al. 2012; Jiao et al. 2014; Yu et al. 2014; Zhou et al. 2015b) as well as several other diseases (Plouffe et al. 2015).”
Self-citationThe Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387
“YAP/TAZ regulation by GPCRs is altered in some human cancers (124, 125).”
BackgroundSelf-citationThe emerging roles of YAP and TAZ in cancer
Moroishi, T., Hansen, C. G., & Guan, K.-L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3876 · Cited by 1,145
Self-citationYAP/TAZ upstream signals and downstream responses
Totaro, A., Panciera, T., & Piccolo, S. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0142-z · Cited by 1,086
The Hippo Signaling Pathway in Development and Disease
Zheng, Y., & Pan, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.003 · Cited by 867
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
Self-citationJager, M. J., Shields, C. L., Cebulla, C. M., Abdel-Rahman, M. H., Grossniklaus, H. E., Stern, M.-H., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 825
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Self-citationAlternative Wnt Signaling Activates YAP/TAZ
Park, H. W., Kim, Y. C., Yu, B., Moroishi, T., Mo, J.-S., Plouffe, S. W., Meng, Z., Lin, K. C., Yu, F.-X., Alexander, C. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.013 · Cited by 705
Self-citationSchadendorf, D., Fisher, D. E., Garbe, C., Gershenwald, J. E., Grob, J.-J., Halpern, A., Herlyn, M., Marchetti, M. A., McArthur, G., Ribas, A., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.3 · Cited by 613
YAP and TAZ: a nexus for Hippo signaling and beyond
Hansen, C. G., Moroishi, T., & Guan, K.-L. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.05.002 · Cited by 574
Self-citationNerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling
Hayakawa, Y., Sakitani, K., Konishi, M., Asfaha, S., Niikura, R., Tomita, H., Renz, B. W., Tailor, Y., Macchini, M., Middelhoff, M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.11.005 · Cited by 573
Self-citationThe Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Interplay between YAP/TAZ and Metabolism
Koo, J. H., & Guan, K.-L. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.010 · Cited by 472
Self-citationUveal melanoma: From diagnosis to treatment and the science in between
Chattopadhyay, C., Kim, D. W., Gombos, D. S., Oba, J., Qin, Y., Williams, M. D., Esmaeli, B., Grimm, E. A., Wargo, J. A., Woodman, S. E., et al. (2016) · Cancer · doi:10.1002/cncr.29727 · Cited by 443
Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.04.001 · Cited by 420
YAP/TAZ functions and their regulation at a glance
Pocaterra, A., Romani, P., & Dupont, S. (2020) · Journal of Cell Science · doi:10.1242/jcs.230425 · Cited by 367
Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms
Van Weelden, G., Bobiński, M., Okła, K., Van Weelden, W. J., Romano, A., & Pijnenborg, J. M. A. (2019) · Marine Drugs · doi:10.3390/md17010032 · Cited by 330
The Hippo pathway in intestinal regeneration and disease
Hong, A. W., Meng, Z., & Guan, K.-L. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.59 · Cited by 326
Self-citationThe Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 326
Advances in the clinical management of uveal melanoma
Carvajal, R. D., Sacco, J. J., Jager, M. J., Eschelman, D. J., Olofsson Bagge, R., Harbour, J. W., Chieng, N. D., Patel, S. P., Joshua, A. M., & Piperno-Neumann, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00714-1 · Cited by 278
Carvajal, R. D., Piperno-Neumann, S., Kapiteijn, E., Chapman, P. B., Frank, S., Joshua, A. M., Piulats, J. M., Wolter, P., Cocquyt, V., Chmielowski, B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.1090 · Cited by 271
Uveal melanoma: Towards a molecular understanding
Smit, K. N., Jager, M. J., de Klein, A., & Kiliҫ, E. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100800 · Cited by 264
Regulation of TEAD Transcription Factors in Cancer Biology
Huh, H., Kim, D., Jeong, H.-S., & Park, H. (2019) · Cells · doi:10.3390/cells8060600 · Cited by 259
Feng, X., Arang, N., Rigiracciolo, D. C., Lee, J. S., Yeerna, H., Wang, Z., Lubrano, S., Kishore, A., Pachter, J. A., König, G. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.009 · Cited by 237
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Self-citationHansen, C. G., Ng, Y. L. D., Lam, W.-L. M., Plouffe, S. W., & Guan, K.-L. (2015) · Cell Research · doi:10.1038/cr.2015.140 · Cited by 212
Self-citationZhang, H., Ramakrishnan, S. K., Triner, D., Centofanti, B., Maitra, D., Győrffy, B., Sebolt-Leopold, J. S., Dame, M. K., Varani, J., Brenner, D. E., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aac5418 · Cited by 196
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
Regulation of RhoA GTPase and various transcription factors in the RhoA pathway
Kim, J., Islam, R., Cho, J. Y., Jeong, H., Cap, K., Park, Y., Hossain, A. J., & Park, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26487 · Cited by 131
MRTF potentiates TEAD‐YAP transcriptional activity causing metastasis
Kim, T., Hwang, D., Lee, D., Kim, J., Kim, S., & Lim, D. (2017) · The EMBO Journal · doi:10.15252/embj.201695137 · Cited by 114
The Hippo Signaling Pathway in Drug Resistance in Cancer
Zeng, R., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13020318 · Cited by 89
TAZ and YAP are frequently activated oncoproteins in sarcomas
Fullenkamp, C. A., Hall, S. L., Jaber, O. I., Pakalniskis, B. L., Savage, E. C., Savage, J. M., Ofori-Amanfo, G. K., Lambertz, A. M., Ivins, S. D., Stipp, C. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8979 · Cited by 78
Yu, O. M., Benitez, J. A., Plouffe, S. W., Ryback, D., Klein, A., Smith, J., Greenbaum, J., Delatte, B., Rao, A., Guan, K.-L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0301-5 · Cited by 62
Self-citationGenome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
Zeng, H., Castillo-Cabrera, J., Manser, M., Lu, B., Yang, Z., Strande, V., Begue, D., Zamponi, R., Qiu, S., Sigoillot, F., et al. (2019) · eLife · doi:10.7554/elife.50223 · Cited by 57
“Moreover, majority of human uveal melanomas, driven by activating mutations in Gαq/11 proteins, depend on YAP signaling for tumorigenesis (Yu et al. 2014).”
BackgroundTargeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma
Raymond, J. H., Aktary, Z., Larue, L., & Delmas, V. (2022) · Cancers · doi:10.3390/cancers14030706 · Cited by 20
Metadata
- Authors
- Yu, F.-X., Luo, J., Mo, J.-S., Liu, G., Kim, Y. C., Meng, Z., Zhao, L., Peyman, G., Ouyang, H., Jiang, W., Zhao, J., Chen, X., Zhang, L., Wang, C.-Y., Bastian, B. C., Zhang, K., & Guan, K.-L.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 25
- Issue
- 6
- Pages
- 822-830
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2092622990
- Cited by
- 463
- References
- 32
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.